AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research

Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through AmpligenOCALA, Fla., March 25, 2024 -- AIM ImmunoTech Inc.   today announced the...

Related Keywords

United States ,American ,Thomask Equels , ,Facebook ,Exchange Commission ,Immunotech Inc ,Erasmus University Medical Center ,Early Access Program ,Linkedin ,Astrazeneca ,Clinical Cancer Research ,Advanced Pancreatic Cancer ,Anti Tumor Immunity ,Dendritic Cell Mediatedt Responses ,Executive Officer Thomas ,Pancreato Biliary Surgeon ,Private Securities Litigation Reform Act ,Markets ,